Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Summary

An open-label, multi-center, phase 2 study of the efficacy of denosumab in subjects with giant cell rich tumors of bone. The population will consist of subjects with the following tumor types: aneurysmal bone cysts (ABC), giant cell granuloma (GCG) and other giant cell rich lesions (primary bone, non-malignant).

Timeline

Start

2018-06-18

Primary completion

2021-06

Completion

2023-06

Publications

• Lipplaa A, Schreuder WH, Pichardo SEC, Gelderblom H. Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study. Oncologist. 2023 Nov 2;28(11):1005-e1104. doi: 10.1093/oncolo/oyad196.

Drugs

Indications